pharmaphorum4d
Libtayo gets a double with EU approvals in skin, lung cancer
Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...
pharmaphorum4y
Sanofi/Regeneron's Libtayo set for new skin cancer use
Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab ... time a medicine has shown a clinical benefit in basal cell carcinoma patients who have progressed or are ...
Hosted on MSN2mon
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...
Nasdaq26d
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung ...
Business Wire1mon
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ... in Non-Small Cell Lung Cancer (NSCLC).
Hosted on MSN5mon
Regeneron Gains 13.5% Year to date: How to Play the Stock?
It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...